The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Intergroup Rhabdomyosarcoma Study-IV: Results for Patients With Nonmetastatic Disease
Abstract
PURPOSE: The study goal was to improve outcome in children with rhabdomyosarcoma by comparing risk-based regimens of surgery, radiotherapy (RT) and chemotherapy. PATIENTS AND METHODS: Eight hundred eighty-three previously untreated eligible patients with nonmetastatic rhabdomyosarcoma entered the Intergroup Rhabdomyosarcoma Study-IV (IRS-IV) (1991 to 1997) after surgery and were randomized treatment by primary tumor site, group (1 to 3), and stage (I to III). Failure-free survival (FFS) rates and survival were the end points used in comparisons between randomized groups and between patient subgroups treated on IRS-III and IRS-IV. Most patients were randomized to receive vincristine and dactinomycin (VA) and cyclophosphamide (VAC, n = 235), or VA and ifosfamide (VAI, n = 222), or vincristine, ifosfamide, and etoposide (VIE, n = 236). Patients with group 3 tumors were randomized to receive conventional RT (C-RT) versus hyperfractionated RT (HF-RT). RESULTS: Overall 3-year FFS and survival were 77% and 86%, respectively. Three-year FFS rates with VAC, VAI, and VIE were 75%, 77%, and 77%, respectively (P = .42). No significant difference in outcome was noted with HF-RT versus C-RT (P = .85 and P = .90, respectively). Overall, patients with embryonal tumors benefited from intensive three-drug chemotherapy in IRS-IV (3-year FFS, 83%). The improvement was seen for patients with stage I or stage II/III, group 1/2 disease, many of whom received VA chemotherapy on IRS-III. Patients with stage 2/3, group 3 disease had similar outcomes on IRS-III and IRS-IV. Three-year FFS for the nonrandomized patient subsets was 75% with renal abnormalities; 81% for paratesticular, group 1 cases; and 91% for group 1/2 orbit or eyelid tumors. Patients with paratesticular primaries had poorer outcomes if they were more than 10 years old (3-year FFS, 63% v 90%). Myelosuppression occurred in most patients, but toxic deaths occurred in less than 1%. CONCLUSION: VAC and VAI or VIE with surgery (with or without RT), are equally effective for patients with local or regional rhabdomyosarcoma and are more effective for embryonal tumors than therapies used previously. Younger patients with group 1 paratesticular embryonal tumors and all patients with group 1/2 orbit or eyelid tumors can usually be cured with VA chemotherapy along with postoperative RT for group 2 disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
The Third Intergroup Rhabdomyosarcoma Study.
Crist, W., Gehan, E. A., Ragab, A. H., Dickman, P. S., Donaldson, S. S., Fryer, C., Hammond, D., Hays, D. M., Herrmann, J., & Heyn, R. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.3.610 · Cited by 999
Self-citationMiser, J. S., Kinsella, T. J., Triche, T. J., Tsokos, M., Jarosinski, P., Forquer, R., Wesley, R., & Magrath, I. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.8.1191 · Cited by 317
Biology and therapy of pediatric rhabdomyosarcoma.
Pappo, A. S., Shapiro, D. N., Crist, W. M., & Maurer, H. M. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.8.2123 · Cited by 296
Self-citationCrist, W. M., Garnsey, L., Beltangady, M. S., Gehan, E., Ruymann, F., Webber, B., Hays, D. M., Wharam, M., & Maurer, H. M. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.3.443 · Cited by 286
Self-citationCommon Solid Tumors of Childhood
Crist, W. M., & Kun, L. E. (1991) · New England Journal of Medicine · doi:10.1056/nejm199102143240706 · Cited by 208
Self-citationCommon and variant gene fusions predict distinct clinical phenotypes in rhabdomyosarcoma.
Kelly, K. M., Womer, R. B., Sorensen, P. H., Xiong, Q. B., & Barr, F. G. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.5.1831 · Cited by 203
Heyn, R., Haeberlen, V, Newton, W. A., Ragab, A. H., Raney, R. B., Tefft, M., Wharam, M., Ensign, L. G., & Maurer, H. M. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.2.262 · Cited by 192
Self-citationLawrence, W., Gehan, E. A., Hays, D. M., Beltangady, M., & Maurer, H. M. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.1.46 · Cited by 188
Self-citation(1993) · doi:10.1002/1097-0142(19930301)71:5<1904::aid-cncr2820710530>3.0.co;2-x
(1988) · doi:10.1002/1097-0142(19880115)61:2<209::aid-cncr2820610202>3.0.co;2-l
Cited by
The anti-angiogenic basis of metronomic chemotherapy
Kerbel, R. S., & Kamen, B. A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1369 · Cited by 1,397
Skapek, S. X., Ferrari, A., Gupta, A. A., Lupo, P. J., Butler, E., Shipley, J., Barr, F. G., & Hawkins, D. S. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0051-2 · Cited by 875
Sorensen, P. H. B., Lynch, J. C., Qualman, S. J., Tirabosco, R., Lim, J. F., Maurer, H. M., Bridge, J. A., Crist, W. M., Triche, T. J., & Barr, F. G. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.03.137 · Cited by 742
Self-citationNeurofibromatosis type 1: a multidisciplinary approach to care
Hirbe, A. C., & Gutmann, D. H. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70063-8 · Cited by 626
Breneman, J. C., Lyden, E., Pappo, A. S., Link, M. P., Anderson, J. R., Parham, D. M., Qualman, S. J., Wharam, M. D., Donaldson, S. S., Maurer, H. M., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.129 · Cited by 470
Self-citation
Metadata
- Authors
- Crist, W. M., Anderson, J. R., Meza, J. L., Fryer, C., Raney, R. B., Ruymann, F. B., Breneman, J., Qualman, S. J., Wiener, E., Wharam, M., Lobe, T., Webber, B., Maurer, H. M., & Donaldson, S. S.
- Venue
- Journal of Clinical Oncology
- Published
- 2001-06-15
- Volume
- 19
- Issue
- 12
- Pages
- 3091-3102
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1926287352
- Cited by
- 1,087
- References
- 13
- FWCI
- 24.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.